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Since the performance of surgical procedures of the axilla in the treatment of early breast cancer is decreasing, the
role of axillary ultrasound (AUS) as staging procedere has newly to be addressed. The aim of this study was to
determine which patient or histopathological characteristics are related to false-negative AUS. In a retrospective
study design data of 470 women with primary breast cancer were collected from patient charts and imaging and
pathology records were reviewed. True positive and false negative axillary ultrasound groups were compared in
terms of tumor size, histological subtype, grade, estrogen receptor (ER) and HER2 status, proliferation index, number
and size of nodal metastases, extracapsular extension (ECE) and lymphovascular invasion (LVI). Of 470 patients, 166
(35%) were node positive, 79 of them with suspicious AUS. Factors associated with false negative AUS by univariate
analysis were included in a multivariate model. By multivariate analysis, only size of nodal metastases was an
independent factor for false negative AUS. In the sentinel lymph node biopsy (SLNB) subgroup, 45% of patients had
nodal metastasis size less than or equal to 5 mm. In conclusion, AUS in preoperative staging of early stage breast
cancer is limited by small size of metastases in a substantial number of patients. Prospective studies have to show
whether small metastatic deposits leaving in patients in case of no axillary surgery have no negative effect on
disease free and overall survival.Introduction
During the last decades, axillary lymph node metastases
have been one of the most important prognostic para-
meters in patients with breast cancer. Today, in clinic-
ally negative axilla surgical (cN0) staging with sentinel
lymph node biopsy (SLNB) represents the standard of
care. However, more than 60% of all primary breast can-
cers do not have lymph node metastases. Due to the
introduction of national screening programs a greater
proportion of breast cancers are detected in an early
stage with an increasing number of nodal negative dis-
ease. For these patients, even SLNB represents an
overtreatment and may not be indicated. For many solid
tumours the role of lymph node dissection is yet con-
troversial, since it does not influence mortality. It is* Correspondence: angrit.stachs@kliniksued-rostock.de
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in any medium, provided the original work is pcommonly acknowledged that the risk of developing
metastases depends mainly on the biological behavior of
the primary (seed and soil theory) (Engel et al. 2006).
Moreover, a series of carefully performed prospective
randomized trial focusing on axillary surgery in breast
cancer exist showing a high rate of locoregional control
achieved with multimodality therapy, even without axil-
lary lymph node dissection (ALND) (Fisher et al. 2002;
Group et al. 2006; Martelli et al. 2005; Giuliano et al.
2011). In fact, with the increasing influence of breast
cancer biology on adjuvant treatment decisions, the
relevance of nodal status is decreasing. It arises the
question whether the information is necessary which we
gain from identifying and examining the sentinel node
(Gerber et al. 2011). Two planned prospective trials
are focussing on this topic: SOUND (Sentinel Node vs.
Observation after axillary Ultrasound) and German/
Austrian INSEMA-Trial, an Intergroup study to com-
pare axillary SLNB vs. no axillary surgery in patientsn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patient characteristics (n = 470)
Patients pN+ % p
Age (years) n.s.
≤50 74 28 37.8
>50 396 138 34.8
BMI n.s.
<25 180 60 33.3
25-29.9 165 59 35.8
≥30 124 46 37.1
Tumour stage <0.001
pT1 278 62 22.3
pT2 164 81 49.4
pT3 & pT4 28 23 82.1
Histological subtype 0.045
Ductal 340 128 37.6
Lobular 44 16 36.4
Others 86 22 25.6
Grading <0.001
G1 67 6 9
G2 261 88 33.7
G3 142 72 50.7
Lymphangiosis <0.001
No 278 33 11.9
Yes 192 133 69.3
Growth pattern <0.001
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2012). In this context, the role of preoperative axillary
ultrasound (AUS) as a staging procedere has newly to
be addressed. There is no doubt, that AUS, carried out
by an experienced examiner, provides valuable informa-
tion in the diagnosis of axillary metastatic involvement.
But there are no standards defining sonographically sus-
picious lymph nodes. In a systematic review including
16 studies using morphologic criteria for positivity, sen-
sitivity ranged from 26.4% (95% confidence interval [CI]
15.3-40.3%) to 75.9% (56.4-89.7%), and specifity varied
between 88.4% (82.1-93.1%) and 98.1% (90.1-99.9%).
Combining AUS with sonographically guided fine-
needle aspiration (AUS-FNA), sensitivity varied be-
tween 30.6% (22.5-39.6%) and 62.9% (49.7-74.8%) and
specificity reached nearly 100% (94.8-100%) (Alvarez
et al. 2006). A recent meta-analysis from Houssami
et al. including 31 studies focusing on ultrasound
guided core needle biopsy (UNB) in preoperative breast
cancer staging showed an estimated sensitivity of 79.6%
(74.1-84.2%) and specificity of 98.3% (97.2-99.2%). Sub-
group analysis revealed that UNB provided more utility
in women with average or higher underlying higher risk
for node metastases (Houssami et al. 2011).
However, the aim of most recent studies dealing with
AUS in breast cancer was to identify women with
lymph node metastases (imaging N1[iN1]) to spare
SLNB and refer them directly to ALND. In view of the
potentially avoidance of axillary surgery in future, the
aim of our study (primary objective) was to identify fac-
tors influencing accuracy of AUS in preoperative breast
cancer assessment. For that reason, we analyzed the
sonographically missing metastatic lymph nodes (false
negatives) at our institution. Secondary, we determined
patients at risk for nodal involvement using tumour
biological parameters as well as nomograms.Unifocal 427 139 32.6
Multicentric 40 25 62.5
ER status n.s.
Positive 383 129 33.7
Negative 87 37 42.5
PR status 0.024
Positive 339 109 32.2
Negative 131 57 43.5
HER2 status n.s.
Negative 432 150 34.7
Positive 38 16 42.1
Ki-67 <0.001
≤14% 161 38 23.6
>14% 282 122 43.3
Total 470 166 35.3Materials and methods
A total of 470 patients with primary breast cancer re-
ferred to our university hospital between February 2008
and January 2010 were enrolled in this retrospective
study. In concordance to the institutional policy breast
ultrasound including AUS was carried out by one of
five experienced examiners before core needle biopsy.
Lymph nodes were identified as abnormal according to
sonographic criteria including absence of a fatty nodal
hilum or a round hypoechoic node. Patients with sono-
graphically negative nodes were subjected to SLNB.
Patients with sonographically positive lymph nodes or
contraindications for SLNB underwent ALND. Second-
ary, completion ALND was carried out in patients
with positive sentinel lymph nodes. Patients with
neoadjuvant chemotherapy were excluded from thisanalysis. The institutional review board approved the
study and informed consent was obtained from all
patients.
Patient charts were reviewed for patient demographics,
primary tumour histology, tumour size, grade, hormone
receptor status, HER2 status, results of AUS, number of
Figure 1 Flow chart of involvement of axillary lymph nodes (n = 470). ALND axillary lymph node dissection, SLNB sentinel lymph node
biopsy, SLN sentinel lymph node, NSLN nonsentinel lymph node.
Table 2 Comparison of axillary lymph node status as





Positive 79 13 92
Negative 87 291 378
Total 166 304 470
Sensitivity, specificity, positive predictive value, negative predictive value and
accuracy of axillary ultrasound in the detection of lymph node metastases:
47.6% (95%CI 40.1; 55.2), 95.7% (92.8; 97.5); 85.9% (77.3; 91.6); 77% (72.5; 80.9)
and 78.7% (74.5; 82.9). SLNB Sentinel lymph node biopsy, ALND Axillary lymph
node dissection, CI Confidence interval.
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of lymph nodes after ALND, number of positive nodes
by histological examination, presence of lymphovascular
invasion (LVI) or extracapsular extension (ECE). For de-
termination of the size of the largest metastatic deposit
of involved lymph nodes histological H&E slides were
reviewed by our pathologist.
Statistical analysis was carried out using the SPSS
19.0 software package (IBM Ehningen, Germany). Sen-
sitivity, specificity, positive predictive value, negative
predictive value, and accuracy of AUS in the detection
of lymph node metastases were calculated. To compare
the proportion of missed axillary metastases between
subgroups, Fisher’s exact (two variables), Pearson chi-
square (three or more nominal variables or linear-by-
linear association tests (three or more ordered vari-
ables) were used. The variables that were significant by
univariate analysis were tested by multivariate logistic
regression, to assess which of them had independent
significance. A p-value <0.05 was considered statisti-
cally significant. All tests were two-sided. Clinical data
were incorporated into the nomogram of the Memorial
Sloan-Kettering Cancer center (MSKCC) to predict
probability of SLN metastases (Bevilacqua et al. 2007).
Discrimination of MSKCC nomogram was analyzed
using receiver-operating characteristic (ROC) curve.
Results
Lymph node metastases and primary tumour pathology
From 470 patients with primary breast cancer, 166 pa-
tients (35.3%) had lymph node metastases. Baseline
characteristics in relation to lymph node status are
presented in Table 1. Concerning the surgical approach,
110 patients were primary treated with ALND. In 92 of
them AUS was positive and 18 patients had contraindi-
cations for SLNB (large tumour size, previous extensivebreast surgery). The remaining 360 patients underwent
SLNB, 76 of them (21.1%) had metastatic involved
lymph nodes. In 75 patients with pN + (sn) completion
ALND was performed with the result of 32 patients
having positive non-SLN (Figure 1).
Axillary US was abnormal in 79 patients with meta-
static lymph nodes and in 13 patients without nodal
involvement. Sensitivity, specificity, positive predictive
value, negative predictive value and accuracy of axillary
US were 47.6%, 95.7%, 85.9%, 77% and 78.7%, respect-
ively (Table 2). The proportion of sonographically missed
axillary metastases was significant lower in large-sized
tumours, grade 3 tumours, presence of lymphangiosis,
ER/PR negative tumours, HER2-positive tumours and
Ki-67 > 14% (Table 3) as well as nodal metastasis size
>5 mm, N2- or N3-disease and extracapsular extension
(Table 4). No differences in the false-negative AUS find-
ings were seen according to age, BMI, histological sub-
type and multifocal/multicentric disease. To evaluate
which of the parameters had independent prognostic
value in the prediction of false-negative AUS, the factors
that were significant by univariate analysis were tested in
a multivariate model. By multivariate logistic regression,
Table 3 False-negative rate of axillary ultrasound (AUS) in
different subgroups of 166 nodal-positive patients
pN+ AUS positive AUS negative p
n n %
Age (years) n.s.
≤50 28 16 12 42.9
>50 138 63 75 54.3
BMI n.s.
<25 60 28 32 53.3
25-29.9 59 24 35 59.3
≥30 46 26 20 43.5
Tumour stage 0.001
pT1 62 20 42 67.7
pT2 81 42 39 48.1
pT3 & pT4 23 17 6 26.1
Histological subtype n.s.
Ductal 128 66 62 48.4
Lobular 16 5 11 68.8
Others 22 8 14 63.6
Grading 0.005
G1 6 1 5 83.3
G2 88 34 54 61.4
G3 72 44 28 38.9
Lymphangiosis 0.001
No 33 7 26 78.8
Yes 133 72 61 45.9
Growth pattern n.s.
Unifocal 139 65 74 53.2
Multicentric 25 14 11 44.0
ER status 0.024
Positive 129 55 74 57.4
Negative 37 24 13 35.1
PR status 0.014
Positive 109 44 65 59.6
Negative 57 35 22 38.6
HER2 status 0.007
Negative 150 66 84 56
Positive 16 13 3 18.8
Ki-67 <0.001
≤14% 38 9 29 76.3
>14% 122 69 53 43.4
Total 166 79 87 52.4
n.s. = not significant.
Table 4 False-negative rate of axillary ultrasound (AUS)








n n n %
Nodal metastasis size * <0.001
≤5 mm 41 4 37 90.2
5.1-10 mm 46 19 27 58.7




N1 (1–3) 86 27 59 68.6
N2 (4–9) 48 28 20 41.7
N3 (≥10) 32 24 8 25.0
Capsular infiltration <0.001
No 83 23 60 72.3
Yes 83 56 27 32.5
* 3 missing value.
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nificant parameter associated with false negative ultra-
sound findings (Table 5). According to the study group,from 166 patients with nodal involvement, lymph node
metastasis size was available in 163 patients. As shown
in Table 4, 41 patients (25.2%) had metastases ≤5 mm,
which were detected with AUS in only in 4 cases (9.8%).
In contrast, from 76 (45.8%) patients with lymph node
metastases >10 mm, 55 (72.4%) were identified by ultra-
sound (Figure 2).
Subgroup: patients with SLNB
The mean age of the 360 patients operated with SLNB
was 63 (range, 29–90) years, and the mean tumour
size was 17.6 (range, 1–68) mm. Patients characteris-
tics and tumour pathologic features are presented in
Table 6. In total, 76 (21.1%) of 360 patients were iden-
tified with pN + (sn) status. Univariate analysis re-
vealed that tumour size (>10 mm), a higher grading,
presence of lymphangiosis and multicentric tumour
growth were associated with positive nodal disease. In
multivariate logistic regression analysis tumour size
and multicentric growth were independent parameters
related to a positive nodal status (Table 7). Application
of the MSKCC nomogram to our sentinel cohort re-
vealed a ROC value of 0.79 (Figure 3).
To evaluate the tumour burden of patients with posi-
tive SLNB, we analyzed number of positive lymph
nodes and size of largest metastastic deposit after com-
pletion ALND. Of 76 patients with positive lymph
nodes after SLNB, one patient declined further axillary
surgery (n = 75). Information about pathological size of
lymph node metastases was available in 73 patients.
Thirteen (17.8%) patients revealed only micrometas-
tases (pN1mi, ≤ 2 mm), N1 disease (1–3 involved
lymph nodes) was present in 55 (72.4%) patients, N2
Table 5 Significant predictors of false-negative axillary
ultrasound (false-negative ratio = OR) in 470 patients
with breast cancer according to univariate and
multivariate logistic regression
Univariate Multivariate
p-value OR (95% CI) p-value
Tumour stage
T1 0,004 1.55 (1.17-2.04) n.s.
T2-4 1
Grading
G1/2 0.003 1.61 (1.16-2.24) n.s.
G3 1
Lymphangiosis
No 0.001 1.72 (1.33-2.22) n.s.
Yes 1
ER status
Positive 0.024 1.63 (1.03-2.59) n.s.
Negative 1
PR status
Positive 0.014 1.54 (1.08-2.22) n.s.
Negative 1
HER2 status
Negative 0.007 2.99 (1.067-8.36) n.s.
Positive 1
Ki-67
≤14% <0.001 1.76 (1.34-2.30) n.s.
>14% 1
Size of nodal metastasis
≤10 mm <0.001 2.66 (1.81-3.91) 0,001
>10 mm 1
Nodal stage
N1 <0.001 1.96 (1.41-2.73) n.s.
N2-3 1
Capsular infiltration
No <0.001 2.22 (1.59-3.11) n.s.
Yes 1
OR = Odds ratio; CI = confidence interval; n.s. = not significant.
Figure 2 Boxplot graph illustrating the difference in nodal
metastasis size (mm) in all patients with suspicious (TP = true-
positive) and normal axillary ultrasound (FN = false-negative).
In the TP group mean metastasis size is 15.5 mm (SD 6.80) in
comparison to a mean size of 7.7 mm (SD 5.2) in the FN group
mean (p < 0.001). At a cut-off of 10 mm metastasis size,
approximately 75% of patients with lymph node metastasis ≥10 mm
are detected with AUS, whereas 75% of patients with metastases
<10 mm had normal AUS findings.
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ease (≥ 10 metastatic nodes) in 5 (6.6%) patients. The
mean size of largest metastatic deposit in patients with
positive SLN was 7 (range, 1–31, median 6) mm. Meta-
static deposits ≤ 5 mm were found in 33 of 73 patients
(45%), whereas 16 patients (21.9%) had lymph node
metastases > 10 mm (Figure 4).
A total of 43 (57.3%) from 75 patients with positive
SLN had no further lymph node metastases (NSLN) at
the time of completion ALND. In patients with only onepositive SLN the rate of positive non-SLN was 33.3%
(16/48) (Figure 5).Discussion
The role of preoperative AUS in early stage breast
cancer is well-examined (Alvarez et al. 2006). How-
ever, AUS has a broad range of diagnostic perfomance
and the experience of the examiner is crucial for diag-
nostic precision. The results of our study with sensi-
tivity of 47.6% and specificity of 95.7% confirmed the
unsatifactory sensitivity of AUS in axillary staging.
In an attempt to improve the results of AUS, nu-
merous studies have been done dealing with fine nee-
dle aspiration (FNA) or core needle biopsy (CNB)
of axillary lymph nodes in breast cancer patients.
The meta-analysis of Houssami et al. 2397 including
sonographically guides biopsies (FNA and CNB) of
4830 patients with a median prevalence of lymph
node metastases of 47.2% showed a sensitvity of
75.0% and specificity of 98.5% (Houssami et al. 2011).
However, as shown by a raw data analysis of the men-
tioned studies by Leenders sensitivities ranged from 6
to 63% if all patients were included and not only pa-
tients with suspicious AUS followed by FNA or CNB
(Leenders et al. 2012). That means that addition of
sonographically guided biopsy increases specificity
and may help to identify patients with axillary lymph
Table 6 Patients with sentinel lymph node biopsy (n =
360)
Patients pN + (sn) % p-value
Age (years)
≤50 58 13 22.4 n.s.
>50 302 63 20.9
BMI
<25 146 31 21.2 n.s.
25-29.9 125 26 20.8
≥30 89 19 21.3
Tumour stage
pT1a/b 64 7 10.9 0.009
pT1c 182 32 17.6
pT2 111 37 33.3
Histological subtype
Ductal 259 57 22 n.s.
Lobular 31 8 25.8
Others 70 11 15.7
Grading
G1 63 5 7.9 0.014
G2 211 48 22.7
G3 86 23 26.7
Lymphangiosis
No 250 21 8.4 <0.001
Yes 110 55 50
Growth pattern
Unifocal 335 65 19.4 0.021
Multicentric 22 9 40.9
ER status
Positive 301 64 21.3 n.s.
Negative 59 12 20.3
PR status
Positive 270 57 21.1 n.s.
Negative 90 19 21.1
HER2 status
Negative 336 73 21.7 n.s
Positive 24 3 12.5
Ki-67
≤14% 142 24 16.9 0.067
>14% 194 47 24.2
Total 360 76 21.1
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not exclude lymph node metastases, since the propor-
tion of false negatives reaches 37.1%.
In our study, the prevalence of lymph node metasta-
ses was 35.1% and nodal disease was associated withincreasing tumour size, higher grading, presence of
lymphangiosis, multicentric disease and high Ki-67
proliferation index. Accuracy of AUS reached 78.7%,
but the rate of false negatives was considerable. There
was no difference between several examiners (data not
shown). Due to clinical experience it seems much more
difficult to show lymph nodes sonographically in pa-
tients with markedly increased axillary fatty tissue. Un-
expectedly, we did not found any difference in the false
negatives depending on BMI.
To our knowledge, this is the first study showing the
strong association between false negative AUS and size
of lymph node metastases. Previous studies only differ-
entiated between micro- and macrometastases and
found a higher false negative rate in N1mi stage
(Cools-Lartigue et al. 2013). Leenders et al. showed a
sensitivity to detect micrometastases of 22.2% in com-
parison to a sensitivity to detect macrometastases of
51.9% (Leenders et al. 2012). But we must take into ac-
count the limits of ultrasound according to lesion size.
In our study, 41/163 (25%) patients with N + disease
had a maximum size of nodal metastases ≤5 mm. The
false-negative rate in this subgroup reached 90%. This
can partially be explained by the relatively poor ultra-
sound criteria defining suspicious lymph nodes used in
this study. Other studies have shown a cortical thick-
ness of ≥3 mm to be the most useful predictor of
malignancy (Deurloo et al. 2003; Choi et al. 2009;
Mainiero et al. 2010). However, the increase of sensitiv-
ity is connected with a decrease of specificity, which in
clinical practise means that more patients are selected
for ALND without having metastatic involved lymph
nodes. On the other hands, there remains a consider-
able number of undetected metastatic involved lymph
nodes also in these studies.
We have to ask the question whether other imaging
techniques are able to detect small metastatic involved
lymph nodes. A comparison between physical examin-
ation, mammography, ultrasound and magnetic reson-
ance imaging (MRI) showed no advantage of MRI
regarding the false negatives (Valente et al. 2012).
Mortellaro et al. studied the specific parameters of
MRI for axillary staging of breast cancer and found
that only the presence of any axillary lymph node
without a fatty hilum did correlate with axillary posi-
tivity (Mortellaro et al. 2009). With regard to the
disadvantages including higher costs and patients
physical restrictions there is no role for MRI in the
routine use of preoperative axillary staging. The use
of 18 F-fluorodeoxyglucose-positron emission tomog-
raphy (18 F-FDG-PET) in combination with computed
tomography (CT) to determine axillary nodal status is
an active area of reserach (Peare et al. 2010). A recent
study by Ueda et al. compared the ability of 18FDG-
Table 7 Predictors of Sentinel Lymph Node metastases in 360 patients with breast cancer according to univariate and
multivariate logistic regression
Univariate Multivariate
Variable p-value Metastasis rate ratio (95%CI) p-value
Tumour stage
T1 1
T2 0.002 2.05 (1.38-3.03) 0.019
Grading
G1/2 1
G3 0.014 1.38 (0.9-2.11) n.s.
Lymphangiosis*
No 1
Yes <0.001 5.95 (3.8-9.33)
Growth pattern
Unifocal 1
Multicentric 0.021 2.1 (1.22-3.65) 0.051
Ki-67
≤14% 1
>14% 0,067 2.17 (1.05-4.5) n.s
* Multivariate analysis included all preoperatively known parameters with significant results in univariate calculation (excluding lymphangiosis);
n.s. = not significant.
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both imaging techniques (Ueda et al. 2008). Actually,
the performance of FDG-PET remains to low to re-
place assessment of axillary status by surgical biopsy
and histological examination.Figure 3 Receiver-operating characteristic (ROC) curve
calculation for the MSKCC nomogram applied to the sentinel
cohort of our study population (n = 360). The predictive accuracy
of this model, as measured by the area under ROC curve (AUC) was
0.79 (95%CI 0.73; 0.84).Subgroup of patients with SLNB
Our study revealed metastatic involved SLN in 21.1% of
patients, in subgroups of G1 tumours even 7.9% and
tumour size ≤ 10 mm 10.8%. Multicentric disease and
tumour size were independent risk factors for positive
lymph nodes in multivariate analysis. Although SLNB
is an extremely safe procedure with low morbidity, it
has been suggested that patients with a low risk of axil-
lary lymph node metastases should be spared SLNB
(Viale et al. 2005). Concerning the multiparameterFigure 4 Metastasis size in SLN-positive patients. In 33/73
patients (45.2%) histological metastasis size was maximal 5 mm, 13
of them had micrometastases≤ 2 mm.
Figure 5 SLN-positive patients after ALND (n = 75). Involvement
of non-SLN (NSLN). 43/75 patients (57.3%) with positive SLN had no
further lymph node metastases. In patients with only one positive
SLN the rate of positive NSLN is 33.3% (16/48).
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Kettering Cancer Center (MSKCC) developed a predict-
ive model using nine preoperatively assessable variables
associated with SLN metastasis, the so-called MSKCC
nomogram. The diagnostic performance of this test was
quite accurate with an area under the receiver operating
characteristic (ROC) curve of 0.75 (Bevilacqua et al.
2007). The evaluation of this model in our study popu-
lation as well as other cohorts confirmed the good re-
sults, but until now SLNB has proven as gold standard
in axillary staging (Klar et al. 2009).
In this study cohort, the axillary tumour burden is
low with 45.2% of pN + (sn) patients having a max-
imum size of lymph node metastases ≤ 5 mm and 43.3%
having only one metastatic lymph node after comple-
tion ALND. Currently, there is an ongoing discussion
about the need of completion ALND in pN + (sn) pa-
tients. According to the results of the ACOSOG Z0011
[Giuliano] trial, in patients with clinically negative ax-
illa and one or two SLNs containing metastases treated
with breast conserving therapy and tangential irradi-
ation completion ALND can be omitted (Giuliano et al.
2011). Recent data of the IBCSG 23–01 trial showed no
disadvantage in relapse-free and overall survival in pa-
tients with SLN micrometastases omitting completion
ALND (Galimberti et al. 2013).
One step more would be to totally give up axil-
lary surgery as staging procedure in clinically andsonographically negative axilla. From well-designed
large studies dealing with safety of SLNB it is known
that the rate of false negative SLNB is about 7 to 10%
(Veronesi et al. 2003; Krag DN, Anderson SJ, Julian
TB, Brown AM, Harlow SP, Ashikaga T, Weaver
DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD,
Robidoux A, Scarth HM, Mammolito DM, McCready
DR, Mamounas EP, Costantino JP, Wolmark N &
National Surgical Adjuvant Breast and Bowel Project
2007). But long time follow-up data of the NSAPB
B-32 trial (SLNB + ALND vs. SLNB and ALND only
in case of involved SLN) with 3986 patients and a
mean follow-up time of 95.6 month have shown that
there was no difference in overall survival, disease-
free survival and number of recurrences in both study
groups. Moreover, the rate of axillary node recurrence
was markedly lower than expected. In detail, a total
of 8 women with axillary node recurrence was seen in
contrast to 57 expected cases of axillary recurrence in
the group without ALND (n = 2011) with an under-
lying incidence of lymph node metastases of 29% and
a false negative rate of 9.8% (Krag et al. 2010). Similar
results were shown by Veronesi et al. with a cumula-
tive incidence of axillary metastases of 1% at 5 years
in 3548 patients with SLNB (Veronesi et al. 2009).
However, the 5-year overall survival rate in this series
was 98% with a high percentage of pT1 tumors and
may not be representative for other studies. It re-
mains the question: Can we accept false negative AUS
for nodal metastases ≤10 mm in clinical practice? We
know that pN + (sn) patients with low axillary tumour
burden do not benefit from extensive axillary surgery
in the era of sufficient local (tangential irradiation
after BCS) and systemic adjuvant therapy. Moreover,
the percentage of pN + patients is decreasing due to
mammography screening programs.Conclusion
This study shows that accuracy of preoperative AUS
in early stage breast cancer patients depends mainly
on the size of axillary lymph node metastases. Meta-
static deposits up to 10 mm represent a substantial
number of false negative AUS and remain a diag-
nostic challenge. Otherwise, adjuvant therapy deci-
sions become more and more independent of nodal
involvement and recent studies showed no disad-
vantage in survival in case of potentially missing
metastatic lymph nodes. Future prospective random-
ized studies including preoperative AUS (SOUND
trial, INSEMA trial) will contribute to answer the
question if surgical staging of the clinically and
sonographically inconspicuous axilla is still necessary
in early breast cancer treatment.
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